The dysregulation of cellular cyclin–CDK function as a result of increased expression of cyclin D1, of mutations in CDK4/6 that confer resistance to CDK inhibitors, and of reduced expression of ...

Cyclin-dependent kinases (CDKs ... and five additional genes encoding a more distant group of proteins known as CDK-like (CDKL) kinases. The current nomenclature for CDK proteins includes 11 ...

Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

That deal included a $50 million upfront payment. CDK inhibitors, which treat cancer by blocking overactive cyclin-dependent kinases, are big business in breast cancer. Earlier this month an ...

Poster presentation details are below: Author: Molina et al Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft ...